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Introduction
Early diagnosis of colorectal cancer is crucial for achieving 
cure and is associated with improved survival (1). Molecular 
biomarkers that can identify mucosa at risk of neoplastic 
transformation, before the development of histological 
abnormality, hold the greatest promise. Based on the field 
cancerisation concept (2), the macroscopically normal 
mucosa around a cancer contains biological alterations, 
which occur early on in the cancer process (3). These 
changes contribute to neoplastic transformation without 
affecting the histological appearance of the mucosa. 
Characterisation of this ‘field defect’ around a cancer could 
enable identification of biomarkers of neoplastic risk (4). 
Previous studies have investigated the role of tumour 
suppressor and oncogenes in field cancerisation; however, 
the importance of stromal cells in driving malignant 
epithelial cell growth has only recently come to the 
forefront of cancer research (5,6). Growth signals such as 
the fibroblast growth factors have particularly, been shown 
to contribute to epithelial cell proliferation in several 
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cancers (7). Cellular proliferation and differentiation 
is governed by a family of some 22 fibroblast growth 
factors (8). Fibroblast growth factor 7 (FGF7) is a mitogen 
of mesenchymal origin that acts on a specific FGF receptor, 
FGFR2IIIb. Upon binding, it acts via the MAPK pathway 
to induce epithelial cell proliferation, migration and 
differentiation of epithelial cells (9). Studies in vitro have 
demonstrated that FGF7 contributes to wound repair 
and mucosal healing following a toxic injury to intestinal 
epithelial cells (10). To date there have been conflicting 
reports regarding its role in CRC formation with some 
authors proposing it is overexpressed in tumour tissue (11) 
whilst others indicate expression is no different compared 
with paired normal mucosa (12). Recent interest has focused 
on the role of its receptor, FGFR2b, which has been found 
to be overexpressed in colorectal cancer, suggesting a 
putative role in governing growth of malignant cells (13). 
In contrast, there have been some reports where FGFR2b 
expression has been linked with a less aggressive tumour 
type (14). Thus, it is unclear how FGF7-FGFR2 signalling 
contributes to CRC formation. 
To address this further, this study utilised a novel 
approach by taking serial samples along the colon enabling 
the expression level at the tumour site to be compared to 
that found at distant sites. A separate cohort of control 
subjects was included to determine the expression level 
when there was no mucosal abnormality in the colon. Thus, 
the purpose of this study was twofold; firstly, to ascertain 
the importance of FGF7 and its receptor FGFR2 as an early 
molecular marker in field defects around CRC; secondly, 
downstream FGF7 targets in the tumour and mucosal field 
around a cancer were evaluated to determine how FGF7-
FGFR2 signalling contributes to CRC formation.
Methods
Participants
All participants were provided with written information 
about the study. Written informed consent was gained. The 
study was performed in accordance to the Declaration of 
Helsinki. Ethical approval was acquired from Coventry and 
Warwick Local Research Ethics Committee (MREC ref 
No. 09/H1211/38) as well as Research Governance approval 
and sponsorship from the University Hospital Coventry & 
Warwickshire Research & Development office. 
In total, 51 patients (21 females) were recruited, of 
which, 17 had cancer. There were two patients with 
synchronous lesions therefore 19 cancers were analysed. 
The clinicopathological details for the control subjects 
and cancer patients are given in Table 1; there were no 
significant differences between the two groups. Each cancer 
patient was age and sex matched to two control subjects. 
Control subjects were patients undergoing colonoscopy 
with no endoscopic or histological evidence of mucosal 
abnormality. Colorecl cancer patients were matched to 
control subjects depending upon the site of tumour/polyp; 
left sided tumours to rectal samples and right sided tumours 
to caecal samples. 
Mucosal pinch biopsies were taken from MNM of the 
caecum and rectum at time of endoscopy in control subjects. 
In CRC patients, mucosal biopsies were taken immediately 
after bowel division from the colectomy specimen prior 
to fixation in formalin. Mucosal tissue was taken from the 
resection margin, tumour site and adjacent to the tumour 
(within 1 cm). Once retrieved, all tissue samples were placed 
immediately in RNA later (Life Technologies, UK). Liquid 
nitrogen was used to snap freeze the tissue samples which 
were then stored at −80 ℃.
Extraction of RNA and purity
The mucosal biopsy tissue (~0.2 mg) was utilised to extract 
RNA with a column-based isolation method (RNeasy Mini 
Tissue Kit: Qiagen, UK) according to the manufacturer’s 
instructions. This yielded 30 µL RNA, from which genomic 
DNA was removed using a DNase I Kit (Sigma). Three point 
five µL (1,000 U/mL) DNase I digestion enzyme combined 
with 3.5 µL reaction buffer were added at room temperature 
for 15 min, after which 3.5 µL stop solution (50 mM EDTA) 
was added. This was then centrifuged (up to 8 s), heated 
(to 70 ℃ for 10 min) and subsequently chilled on ice. A 
spectrophotometer (Nanodrop, Labtech, UK) was used to 
quantify the RNA by measuring the absorbance at 260 nm 
using duplicate samples (1.5 µL). In order to determine RNA 
purity, the ratio was calculated between absorbance at 260/ 
280 nm and at 260/230 nm. Only RNA samples with values 
between 1.8 and 2.1 were utilised for experiments. 
Synthesis of complimentary (cDNA) 
A Bioline kit (No. BIO-65026) was used to synthesise 
complimentary DNA (cDNA). The following were added to 
a 200 µL sterile microcentrifuge tube: 1 µL 10 mM dNTP 
mix (Invitrogen, UK), 1 µL random hexamers 50–250 ng 
(Bioline, UK), 250 ng RNA and RNAse free water to make 
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Table 1 Clinico-pathological details of patients with colorectal cancer and matched controls
Variables Cancers (n=17) Controls (n=33) P value
Age, years, median (range) 70 (64.5–79) 72 (62.5–77.5) 0.621
Sex (male:female) 10:7 20:14 0.881
BMI, mean ± SD 25.1±4.18 26.0±7.3 0.552
Operation
Right hemicolectomy 5
Extended right hemicolectomy 4
Anterior resection 9
En-bloc resection 1
Use of neoadjuvant therapy
Short course radiotherapy 1
Chemotherapy 1
None 15
pT-stage
pT0 0
pT1 4
pT2 2
pT3 7
PT4 6
pN-stage
pN0 11
pN1 5
pN2 3
up a 10 µL solution.
Samples were spun and heated to 70 ℃ (for 10 min) and 
chilled on ice (further 2 min). Ten µL reverse transcription 
mastermix was added to the samples (1 µL RNase inhibitor, 
4 µL of 5× reaction buffer, 0.5 µL reverse transcriptase 
(200 U/µL) with RNase free water to make up a volume of 
10 µL). This resulted in in a final total volume of 20 µL. 
Following incubation at room temperature (5 min), the 
samples were placed in a thermocycler (Biorad, UK). Each 
sample was heated for 5 min at 37 ℃, for 55 min at 42 ℃ 
and for 15 min at 70 ℃ to generate the required cDNA. 
Quantitative real-time polymerase chain reaction (qRT-PCR)
To undertake qRT-PCR, an ABI 7500 standard Sequence 
Detection System (Applied Biosystems, UK) was used. In 
a 96 well plate, reactions were primed in 25 µL volumes 
containing 1 µL cDNA, 12.5 µL Taqman universal PCR 
mastermix (Applied Biosystems, UK) and TaqmanTM Gene 
Expression Assay (Applied Biosystems, UK).
In each reaction, an endogeneous control was used 
which was the housekeeping gene 18 S (ribosomal RNA). 
Triplicate samples were processed in order to improve 
accuracy of results. Each sample was heated to 50 ℃ 
(2 min), 95 ℃ (10 min) and 95 ℃ for 15 seconds over 
40–44 cycles, followed by 60 ℃ (1 min). To measure gene 
expression, commercially available Taqman primers were 
utilised [Applied Biosystems, UK, FGFR2 (Hs01552918_
m1) and FGF7 (Hs00940253_m1)]. For all reactions, the 
primers for the housekeeping and target gene were placed 
together in the same well. ΔCt was calculated by deducting 
Ct of the housekeeping gene from Ct of the target gene. 
ΔCt for each sample was calculated by averaging across the 
triplicates. The inverse of the ΔCt is a measure of the level 
of gene expression and was utilised in statistical analysis. In 
order to determine differences in gene expression between 
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groups, the relative fold change was calculated using the 
formula 2−ΔΔCt where ΔΔCt is the difference between the ΔCt 
for the control sample and ΔCt for the test sample, which 
could either be the cancer/polyp sample, the resection 
margin or the tissue adjacent to the cancer/polyp (15).
Extraction of protein 
Protein was extracted from the colonic samples that had 
been snap frozen. After homogenising each tissue sample, 
1 mL of protein lysis buffer was added. This contained 
5 mL of 1× radioimmunoprecipitation (Millipore, UK) 
in which 100 µL of protease and phosphatase inhibitors 
[8 mg sodium fluoride (Fisher Scientific, UK) and 20 mg 
sodium vanadate (Acros Organics) in 2 mL 1× RIPA 
with 2 Roche Complete Mini protease inhibitor cocktail 
tablets)] were dissolved. The Bio-Rad detergent compatible 
protein assay kit (Bio-Rad Laboratories, CA, USA) was 
used to measure protein concentration. A series of known 
dilutions of bovine serum albumin (BSA, fraction V, Sigma, 
UK) (2 µg/µL) were utilised to construct a standard curve 
of protein concentration against absorbance. Finally, a 
spectrophotometer (Tecan, UK) was used to measure 
absorbance at a 595 mm wavelength to enable calculation of 
the protein concentration (µg/µL).
Western blot analysis
This was performed using a 7.5–10% polyacrylamide gel 
(Geneflow Ltd, Fradley, UK) for which 25–30 µg of protein 
was loaded onto the gel. As per protocol, the proteins were 
resolved over 60–90 min using SDS-PAGE by applying 
a current at 100 V. The proteins were transferred to 
Immobilon-P transfer membranes 0.45 µm pore size (Fisher 
Scientific, UK). Initially, the membrane was incubated in 
0.2% I-Block PBS-tween (PBST) for 60 min. It was then 
transferred into an incubator at 4 ℃ overnight containing 
primary rabbit-derived antibody (Cell Signalling & Abcam, 
UK). Measurement of β-actin expression ensured equal 
amounts of protein were loaded. After washing in PBST, 
membranes were incubated in either horseradish peroxidase 
antibody produced in goat or anti-rabbit IgG (whole 
molecule), IgG fraction of antiserum and buffered aqueous 
solution (Sigma No. A9169, USA). Visualisation of protein 
bands was achieved using chemiluminescence with ECL/
ECL+ (GE Healthcare, UK) and exposure on hyperfilm MP 
(Fisher Scientific, UK). Protein expression was estimated 
by measuring intensity of exposure with densitometry 
(GeneTool software, Syngene, UK). All values for protein 
expression were normalised by subtracting the intensity of 
exposure obtained for β-actin.
Statistical calculations 
All statistical calculation and analysis were performed 
using SPSS version 22 (SPSS Inc, Chicago, Illinois, USA). 
Raw mRNA expression values were log10 transformed to 
normalise the data prior to statistical analysis. The unpaired 
t-test was used to compared the expression levels between 
cancer patients and control subjects. Comparison of gene 
or protein expression amongst samples taken at different 
points along the colon in the same colorectal cancer patient 
was achieved using the paired t-test. A P value of <0.05 was 
considered significant. 
Results
Dysregulation of FGF7 gene expression 
In patients with colorectal cancer, there was upregulation 
of FGF7 at multiple points along the colon (see Figure 1) 
including the resection margin (∆∆CT 21.1), tumour tissue 
itself (∆∆CT 21.4) and its adjacent MNM (
∆∆CT 20.9). This 
was in contrast to control subjects (∆∆CT 22.6). However, 
its receptor, FGFR2 was significantly down regulated only 
in the tumour tissue (∆∆CT 21.2 in tumour tissue compared 
to ∆∆CT 19.4 for controls, P<0.001). Conversely, expression 
of FGFR2 at the resection margin (∆∆CT 19.4) and in the 
adjacent MNM (∆∆CT 19.6) did not differ when compared 
to control subjects. Using the paired t test, comparison 
was made of samples taken along the colon in individual 
colorectal cancer patients. This showed significant 
downregulation of both FGF7 (P=0.036) and FGFR2 
(P=0.013) in the tumour tissue compared to the resection 
margin. 
There was negative correlation between FGF7 and 
FGFR2 gene expression in control subjects (see Figure 2) 
but no correlation was not observed in tumour tissue. 
Akt pathway key for FGF7-FGFR2 signalling axis 
Western blot analysis demonstrated reduced protein 
expression of FRS2α and phospho-FRS2α in tumour tissue 
compared to samples taken from the resection margin. 
This would suggest that the downstream effects of FGF7 
signalling was reduced only at the tumour site. In addition, 
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Figure 1 Mean gene expression level of FGF7 (A) and FGFR2 (B) in caecal or rectal samples taken from control subjects compared to 
samples taken from tumour tissue, adjacent MNM and resection margin of colectomy specimen from CRC patients. Statistical analysis using 
unpaired t-test: *P<0.05; ***P<0.001; NS, non-significant.
Figure 2 FGF7 and FGFR2 correlation. Mean gene expression level of FGF7 and FGFR2 plotted against each other for control samples 
(n=71) and tumour samples (n=19). Pearson correlation coefficient and P value are displayed. 
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there was also a reduction in Akt protein expression but no 
differences were noted in Erk 1/2 expression (Figure 3A,B,C). 
Protein expression levels were similar in tissues taken from 
the resection margin and tissue adjacent to tumour. 
Discussion
This study has identified FGF7 as a putative biomarker of 
CRC field cancerisation utilising a well-matched cohort 
of cancer patients and control subjects. The use of serial 
samples taken along the colectomy specimen enabled 
changes in signalling of the FGF7-FGFR2 axis to be 
elucidated. FGFR2 and its downstream targets, FRS2α 
and Akt were downregulated in the tumour samples 
indicating that malignant transformation is accompanied 
by loss of FGF7 activity through the Akt and not the Erk 
pathway. This highlights that at the tumour site, cellular 
differentiation is lost (Akt pathway) whilst proliferation (Erk 
pathway) is preserved. 
There have been several reports highlighting that 
FGF7 acts as a mitogen and therefore would be expected 
to augment epithelial cell growth. However, studies 
investigating tissue expression in colorectal cancer have 
been inconclusive in elucidating the precise role of FGF7 in 
tumour formation (11,12,14). Our study has demonstrated 
distinct differences in gene expression of FGF7-FGFR2 
that occur only in tumour tissue and not at distant colonic 
sites. The correlation between FGF7 and FGFR2 gene 
expression noted in control subjects was lost at the tumour 
site. An alteration in FGFR trafficking may be responsible 
for this observation and may accompany malignant 
transformation. Upon activation, in a physiological 
environment, FGFRs undergo endocytosis which decreases 
the number of receptors present in the membrane. Thus, 
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Figure 3 Western blot analysis. (A) Protein expression of FRS2α and pFRS2α measured using Western blot analysis. Paired t-test used to 
determine statistical difference between expression at tumour site and adjacent to tumour compared to expression at resection margin. The 
ratio of pFRS2/FRS2 comparing tumour and resection margin is displayed. (B) Protein expression of phospho-Erk (pErk), Erk, phospho-
Akt (pAkt) and Akt measured using Western blot analysis. Paired t test used to determine statistical difference between expression at tumour 
site and adjacent to tumour compared to expression at resection margin. (C) Ratio of the phosphorylated form to unphosphorylated form. *, 
the P value comparing expression at the tumour site compared to the resection margin is shown.
through negative feedback, FGFR activity is autoregulated; 
disruption of this process can result in disordered growth 
factor acitivty contributing to cancer formation (16). 
Similarly, others have shown that well differentiated 
colorectal tumours and those with shallow wall invasion 
have greater FGFR2 expression (14) compared to poorly 
differentiated tumours implying that in aggressive tumours, 
the FGFR2 signal is lost. Examples of other cancers where 
FGFR2 expression is lost include cancers of the salivary 
gland, bladder and prostate (17-19). This implies that the 
FGF7-FGFR2 axis may actually protect against toxic injury 
and neoplastic transformation. 
Our study investigated this hypothesis further by 
measuring the protein expression of certain FGF7 
downstream targets. We found that Akt protein expression 
is reduced at the tumour site only whilst Erk expression is 
maintained. Despite being activated by FGF7, these two 
pathways have been shown to play distinct roles. A study on 
pancreatic duct cells demonstrated that the MEK-Erk 1/2 
pathway was important for proliferation and the Akt pathway 
played a role in cell differentiation (20). Hence, in our study 
with colorectal cancer, results suggest that FGF7 may have 
lost its ability to regulate cell differentiation as Akt expression 
was reduced. However, activity via the MEK-Erk 1/2 pathway 
was preserved suggesting that cell proliferation was retained. 
Others have shown that the effects of FGF7 on cell growth in 
vitro may differ depending upon whether it is a cancer cell or 
normal epithelial cell. FGF7 could not stimulate tumour cells 
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to proliferate but was a strong mitogen for normal epithelial 
cells (12). Similarly, only primary, immortalised keratinocytes 
could by stimulated to grow by recombinant FGF7; it had 
no effect upon malignant head and neck squamous cancer 
cells (21). If FGF7 activity is blocked by a neutralising 
antibody, cell proliferation of normal keratinocytes is 
blocked; there is no effect on malignant cells. Unlike normal 
cells, malignant cells did not express FGFR2b. Therefore, 
FGF7 could not stimulate cell proliferation in a paracrine 
manner as it was able to in normal cells. Taken together, our 
results imply that it may not be the ability of FGF7 to drive 
cell proliferation that is important but rather, the loss of its 
ability to regulate cell differentiation that could contribute to 
malignancy. 
Due to the limitations in tissue availability, our study 
was unable to evaluate expression of the specific isoform 
of the FGFR2 receptor. There is emerging evidence 
proposing that the transformation of isoforms for example 
from isoform FGFR2IIIb to isoform FGFR2IIIc could be 
associated with a more aggressive cancerous phenotype. 
Such a class switch may be important in driving the 
malignant process and holds potential for therapeutic 
agents in the future (22). At present, the precise role of this 
receptor transition in colorectal cancer is unclear and given 
the changes in gene expression we observed, it was felt that 
it was more important to investigate downstream signalling 
rather than receptor class switch. 
In conclusion, we have demonstrated that FGF7 is 
upregulated in patients with colorectal cancer compared 
with control subjects. From these findings, we postulate 
that FGF7 plays a role in field cancerisation and could be 
utilised in a screening population to identify those patients 
with colorectal cancer or in those with cancer or polyps, 
to ultimately help elucidate who is at most risk of further 
neoplasia. A further novel finding is that signalling along 
the FGF7/FGFR2 cascade is disrupted only in the tumour 
tissue and not in tissue taken adjacent to the tumour. 
Thus, it is possible that reduced FGF7 activity contributes 
directly to the neoplastic process or that the malignant cells 
develop mutations that inactivate this pathway. Regardless 
of whether the changes observed are a cause or consequence 
of malignancy, specific directed therapy (chemo or 
nutraceutical) which has the ability to restore the balance of 
FGF7 would be welcome. 
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